Myasthenia Gravis Drugs: Pyridostigmine, Immunotherapy and New Targeted Treatments

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products.

Overview

Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission, most commonly involving acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies. Weakness worsens with repeated activity and improves with rest, but respiratory or bulbar deterioration can be life-threatening. Treatment combines symptomatic acetylcholinesterase inhibition, immune-directed therapy and selected thymus management [1,2].

Symptomatic acetylcholinesterase inhibition

Pyridostigmine reversibly inhibits acetylcholinesterase in the neuromuscular junction, prolonging acetylcholine action at remaining postsynaptic nicotinic receptors. It can improve fatigable weakness but does not treat the autoimmune cause. Adverse effects include abdominal cramping, diarrhea, sweating, salivation and bradycardia. Excess exposure may cause cholinergic weakness; worsening symptoms require assessment rather than blindly increasing doses [1].

Conventional immunosuppression

Prednisone or prednisolone and steroid-sparing immunosuppressants such as azathioprine and mycophenolate are used depending on disease severity, antibody subtype, comorbidities and pregnancy potential. Rituximab is important in selected refractory disease, particularly MuSK-positive MG. IV immunoglobulin (IVIG) and plasma exchange provide relatively rapid but usually temporary improvement in exacerbations or crisis; mechanical ventilatory support may be essential. Thymectomy is an evidence-based option for selected AChR-positive generalized MG and for thymoma [1,2].

Complement-targeted therapies

Eculizumab, ravulizumab and zilucoplan inhibit terminal complement activation (C5 pathway) and can improve generalized AChR-antibody-positive MG in eligible patients. They increase risk of serious meningococcal infection; vaccination and prophylaxis decisions must follow product and jurisdictional recommendations. These drugs are not equally indicated across all antibody subtypes [2].

Neonatal Fc receptor blockers and other newer agents

Efgartigimod, rozanolixizumab and nipocalimab reduce pathogenic IgG exposure by inhibiting FcRn-mediated IgG recycling. Eligibility differs by antibody status, age and country; for example US efgartigimod labeling expanded in 2026 to include adult generalized MG across serotypes, while other agents have their own restricted indications. Inebilizumab (anti-CD19) was approved in the US in late 2025 for certain generalized MG cases. Confirm availability and indication locally before mentioning them as routine care [2].

Safety, drug interactions and emergency care

Drugs that impair neuromuscular transmission may aggravate MG, including certain aminoglycoside or fluoroquinolone antibiotics, magnesium salts, some antiarrhythmics and neuromuscular blockers. Corticosteroid initiation can transiently worsen weakness, sometimes necessitating careful supervised treatment. Dyspnea, weak cough, dysphagia and rapidly progressive weakness require emergency assessment for myasthenic crisis, not outpatient dose adjustment [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Muscular Dystrophy Association. Myasthenia gravis: medical management, approved targeted treatments. Updated 2026. Available from: https://www.mda.org/disease/myasthenia-gravis/medical-management
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *